Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications
Open Access
- 1 January 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 6 (1) , 286-298
Abstract
We previously reported that N-(4-hydroxyphenyl)retinamide (4HPR) inhibits retinoblastoma tumor growth in a murine model in vivo and kills Y79 retinoblastoma cells in vitro. In this work, we assayed different cell death–related parameters, including mitochondrial damage and caspase activation, in Y79 cells exposed to 4HPR. 4HPR induced cytochrome c release from mitochondria, caspase-3 activation, and oligonucleosomal DNA fragmentation. However, pharmacologic inactivation of caspases by the pan-caspase inhibitor BOC-D-fmk, or specific caspase-3 inhibition by Z-DEVD-fmk, was not sufficient to prevent cell death, as assessed by loss of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide reduction, lactate dehydrogenase release, disruption of mitochondrial transmembrane potential (Δψm), and ATP depletion. We found that 4HPR causes lysosomal membrane permeabilization and cytosolic relocation of cathepsin D. Pepstatin A partially rescued cell viability and reduced DNA fragmentation and cytosolic cytochrome c. The antioxidant N-acetylcysteine attenuated cathepsin D relocation into the cytosol, suggesting that lysosomal destabilization is dependent on elevation of reactive oxygen species and precedes mitochondrial dysfunction. Activation of AKT, which regulates energy level in the cell, by the retinal survival facto]r insulin-like growth factor I was impaired and insulin-like growth factor I was ineffective against ATP and Δψm loss in the presence of 4HPR. Lysosomal destabilization, associated with mitochondrial dysfunction, was induced by 4HPR also in other cancer cell lines, including PC3 prostate adenocarcinoma and the vascular tumor Kaposi sarcoma KS-Imm cells. The novel finding of a lysosome-mediated cell death pathway activated by 4HPR could have implications at clinical level for the development of combination chemoprevention and therapy of cancer. [Mol Cancer Ther 2007;6(1):286–98]Keywords
This publication has 44 references indexed in Scilit:
- Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancerAnnals of Oncology, 2006
- Heat Shock Protein 70 Promotes Cell Survival by Inhibiting Lysosomal Membrane PermeabilizationJournal of Experimental Medicine, 2004
- Lysosomes and mitochondria in the commitment to apoptosis: a potential role for cathepsin D and AIFCell Death & Differentiation, 2003
- Cathepsin D mediates cytochrome c release and caspase activation in human fibroblast apoptosis induced by staurosporineCell Death & Differentiation, 2003
- The chemopreventive agent N-(4-hydroxyphenyl)retinamide induces apoptosis through a mitochondrial pathway regulated by proteins from the Bcl-2 familyOncogene, 2003
- Blockade of the apoptotic machinery by cyclosporin A redirects cell death toward necrosis in arterial endothelial cells: regulation by reactive oxygen species and cathepsin DThe FASEB Journal, 2003
- Ceramide Signaling in Fenretinide-induced Endothelial Cell ApoptosisJournal of Biological Chemistry, 2002
- Mitochondrial Respiration Is Uniquely Associated with the Prooxidant and Apoptotic Effects ofN-(4-Hydroxyphenyl)retinamideJournal of Biological Chemistry, 2001
- The lysosomal protease cathepsin D mediates apoptosis induced by oxidative stressThe FASEB Journal, 2001
- Evidence of a lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia HL-60 cellsCell Death & Differentiation, 2001